Asclepius Meditec

Our journey began in 2011, laying the foundation for the global clinical application of hydrogen medicine. In 2014, the device was recognized as an NMPA "National Innovation" project. Led by Professor Zhong Nanshan, a leading figure in respiratory diseases in China, human clinical trials for chronic obstructive pulmonary disease (COPD) were initiated across nine top-tier hospitals in China. In 2020, three models were approved for market launch and were included by China's National Health Commission in the official treatment guidelines for COVID-19. In 2025, Phase IV clinical studies demonstrated an 80% reduction in the frequency of acute COPD exacerbations and over 90% efficacy in reducing lung nodules. To date, Asclepius has accumulated more than 300 animal and cellular studies and 34 human clinical trials. The 92 major hospitals involved in our research are all among the top 100 hospitals in China (out of more than 30,000 nationwide). To date, among fewer than 120 global publications on hydrogen‑oxygen mixed gas inhalation therapy, Asclepius products have contributed 107, along with the monograph Hydrogen Controls Cancer and product documentation available in 11 languages. Our products hold more than 500 global patents. We are the only company that uses no proton exchange membrane perfluorinated compounds (PFOA/PFSA) and releases no strong-base conductive solution, ensuring complete user safety for life. In November 2025, at the Global Hydrogen Medicine Conference held in Tokyo, we were awarded the "Industrial Breakthrough Innovation Award." We are actively advancing regulatory approvals across the European Union, Russia, Saudi Arabia, and the United States. Our pursuit is to validate the value of hydrogen‑oxygen therapy using the scientific rigor of evidence‑based Western medicine. Water is the best medicine for humanity! It will ultimately become the direction pursued by life sciences.